Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil??)
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (9) , 1263-1271
- https://doi.org/10.2165/00003495-200666090-00008
Abstract
▴ Human papillomavirus (HPV) quadrivalent recombinant vaccine is a mixture of virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. It is administered...Keywords
This publication has 15 references indexed in Scilit:
- Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical TrialMayo Clinic Proceedings, 2005
- Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvantJournal of Immune Based Therapies and Vaccines, 2005
- Vaccination against human papillomavirus infection: a new paradigm in cervical cancer controlVaccine, 2005
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineVaccine, 2004
- Human Papillomavirus Vaccines and Prevention of Cervical CancerAnnual Review of Medicine, 2004
- Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening ProgramsJAMA, 2003
- Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of CausalityJNCI Monographs, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002